Core Viewpoint - The announcements detail the share reduction activities of major shareholders of Suzhou Medisun Medical Technology Co., Ltd., including the results of share reductions by major shareholders and the management of idle raised funds [1][2][8]. Shareholder Reduction Summary - Major shareholder Mr. Weng Kang held 20,857,003 shares, representing 6.81% of the total share capital before the reduction plan [1]. - Mr. Weng Kang's reduction plan involved selling up to 5,214,250 shares, not exceeding 25% of his holdings or 1.70% of the total share capital, from October 16, 2025, to January 15, 2026 [1]. - As of January 12, 2026, Mr. Weng Kang successfully reduced his holdings by 5,213,800 shares, accounting for 1.70% of the total share capital [1]. - Mr. Wu Di planned to reduce his holdings by up to 14,250 shares, not exceeding 25% of his holdings or 0.0047% of the total share capital, during the same period [2]. - Mr. Wu Di successfully reduced his holdings by 14,200 shares, representing 0.0046% of the total share capital [2]. Compliance and Issues - Mr. Weng Kang's share reduction included an incident on December 17, 2025, where he mistakenly increased his holdings by 10,900 shares, constituting a short-term trading behavior [2]. - The company board has emphasized the importance of compliance with trading regulations to prevent similar occurrences in the future [2]. Fund Management Summary - The company approved a plan to manage idle raised funds of up to RMB 200 million for cash management, ensuring it does not affect project progress or fund safety [5]. - As of December 31, 2025, the company redeemed a bank deposit of RMB 90 million, earning a return of RMB 22,500 [6]. - The remaining balance of idle raised funds for cash management was RMB 15 million, with no overdue products reported [6].